Posted by Michael Wonder on 06 Apr 2021
Decision to widen access to secukinumab for psoriatic arthritis and ankylosing spondylitis
1 April 2021 - PHARMAC is pleased to announce a decision to widen funded access to secukinumab (Cosentyx) for the treatment of psoriatic arthritis or ankylosing spondylitis, through an agreement with Novartis New Zealand Limited, from 1 May 2021.
This decision will result in the following changes:
- secukinumab will be funded as a first line biologic for psoriatic arthritis
- secukinumab will be funded as a second line biologic for ankylosing spondylitis
- a new secukinumab pack size will be listed, enabling the dispensing of singular packs
